The US FDA has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for CMT2S.
The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.
Novo Nordisk has taken an interest in a weight-loss implant developed by Californian medtech Vivani Medical, reflecting a broadening of the drugmaker’s strategy to fend off mark ...
Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results